Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Humacyte, Inc.HUMA · Entity 6478 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Humacyte, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.08 · Expires 2036-06-11 | Direct | 80,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 80,000 · Balance 80,000 F1: The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030. |
Filing footnotes · ownership attribution and instrument terms
F1: The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 12, 2026 17:58 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 80,000 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001104659-26-073616 · tm2617880-9_4seq1.xml · derivative · entry 1 Wallace Max N. · CIK 0001877453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 16:32 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 80,000 | $0.00 Strike: $2.41 | $0.00 |
DisclosureSEC source: 0001818382-25-000115 · wk-form4_1750105920.xml · derivative · entry 1 Wallace Max N. · CIK 0001877453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-06-12 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 12, 2026, after which 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 16:12 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 50,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001818382-24-000141 · wk-form4_1718655156.xml · derivative · entry 1 Wallace Max N. · CIK 0001877453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-06-13 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028. Read SEC document |
| May 20, 2024 Filed May 21, 2024 16:08 UTC | Humacyte, Inc. HUMA · Entity 6478 | PurchaseCommon Stock | 3,990 | $6.29 | $25,097.10 |
DisclosureSEC source: 0001818382-24-000067 · wk-form4_1716322124.xml · nonDerivative · entry 2 Wallace Max N. · CIK 0001877453 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Max N Wallace IRA Disclosed balance after: 3,990 Read SEC document |
| May 20, 2024 Filed May 21, 2024 16:08 UTC | Humacyte, Inc. HUMA · Entity 6478 | PurchaseCommon Stock | 4,015 | $6.21 | $24,933.15 |
DisclosureSEC source: 0001818382-24-000067 · wk-form4_1716322124.xml · nonDerivative · entry 1 Wallace Max N. · CIK 0001877453 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Max Wallace SEP IRA Disclosed balance after: 4,015 Read SEC document |
| November 21, 2023 Filed Nov 21, 2023 16:07 UTC | Humacyte, Inc. HUMA · Entity 6478 | Exercise / conversionStock Options (right to buy) · Derivative | 6,564 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001818382-23-000165 · wk-form4_1700600845.xml · derivative · entry 2 Wallace Max N. · CIK 0001877453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,564 shares Expires 2023-11-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2023 Filed Nov 21, 2023 16:07 UTC | Humacyte, Inc. HUMA · Entity 6478 | Exercise / conversionCommon Stock | 6,564 | $1.19 | $7,811.16 |
DisclosureSEC source: 0001818382-23-000165 · wk-form4_1700600845.xml · nonDerivative · entry 1 Wallace Max N. · CIK 0001877453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 16:13 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 8,500 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001818382-23-000094 · wf-form4_168694637062084.xml · derivative · entry 1 Wallace Max N. · CIK 0001877453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2033-06-15 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 15, 2024, after which 1/48 of the option will become exercisable on the 15th of each month through June 15, 2027. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 16:22 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 8,500 | $0.00 Strike: $4.34 | $0.00 |
DisclosureSEC source: 0001818382-22-000093 · wf-form4_165515173318572.xml · derivative · entry 1 Wallace Max N. · CIK 0001877453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2032-06-09 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on June 9, 2023, after which 1/48 of the option will become exercisable on the 9th of each month through June 9, 2026. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 15:31 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 8,500 | $0.00 Strike: $10.03 | $0.00 |
DisclosureSEC source: 0001104659-21-126701 · tm2130120-10_4seq1.xml · derivative · entry 1 Wallace Max N. · CIK 0001877453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2031-10-13 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on October 13, 2022, after which 1/36 of the option will become exercisable on the 13th of each month through October 13, 2025. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:10 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 17,068 | Not disclosed Strike: $6.54 | Not disclosed |
DisclosureSEC source: 0001104659-21-110531 · tm2125954-19_4seq1.xml · derivative · entry 4 Wallace Max N. · CIK 0001877453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,068 Underlying: Common Stock · 17,068 shares Expires 2028-04-12 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:10 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 13,129 | Not disclosed Strike: $2.56 | Not disclosed |
DisclosureSEC source: 0001104659-21-110531 · tm2125954-19_4seq1.xml · derivative · entry 3 Wallace Max N. · CIK 0001877453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,129 Underlying: Common Stock · 13,129 shares Expires 2025-09-01 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:10 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 6,564 | Not disclosed Strike: $1.19 | Not disclosed |
DisclosureSEC source: 0001104659-21-110531 · tm2125954-19_4seq1.xml · derivative · entry 2 Wallace Max N. · CIK 0001877453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,564 Underlying: Common Stock · 6,564 shares Expires 2023-11-22 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:10 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantCommon Stock | 49,986 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-110531 · tm2125954-19_4seq1.xml · nonDerivative · entry 1 Wallace Max N. · CIK 0001877453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,986 F1 · price: On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.